K. Wey

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

R. Levy, M. Czuczman, A. Ho, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IDEC-C 2 B 8 ( Rituximab ) Anti-CD 20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin ’ s Lymphoma

D. Maloney, K. Foon, R. Schilder, 1997 .

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program

M. Czuczman, P. Mclaughlin, F. Cabanillas, 2023, Journal of Clinical Oncology.

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

D. Maloney, K. Foon, R. Schilder, 1997 .

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

I Royston, D. Maloney, K. Foon, 1997, Blood.